DRG uses cookies to improve your experience on this website. Some of the cookies we use are essential for parts of the website to operate. Please be aware that if you continue without changing your cookie settings, you consent to this. For more information on our use of cookies, please review our cookie policy.

Innovation in Oncology: Key Drug Classes, Takeaways and Best Practices for Strategic Planning

Cancer patients have a more favorable outlook today than ever before thanks to major improvements in care developed over recent years, and emerging treatment innovation in the pipeline will continue to transform outcomes.

However, innovation in oncology treatment is a huge challenge – not the least because of the overwhelming heterogeneity of the disease, the ever-changing clinical landscape, the incredible molecular complexity, and the ingenious ways cancer cells develop resistance.

To make the innovation task somewhat more manageable, planning novel drug development should incorporate a strategy rooted in sound scientific principles, built on solid clinical rationale, and one which follows a clear and focused development path.

In this report, our experts provide their perspectives on new therapies shaping the future of the war on cancer, and best practices for planning in the turbulent oncology landscape.

Drug classes covered include:

  • Checkpoint inhibitors
  • CAR T-cell therapies
  • RNA-based therapies
  • PARP inhibitors
  • Antibody-drug conjugates
  • Hormonal agents in prostate and breast cancer

Key topics covered include:

  • Current leading therapies
  • Emerging players, agents and trials to watch
  • Disease management and access issues
  • Perspectives from oncologist KOLs
  • Takeaways for biopharma strategists

 

Complete the form to access your Innovation in Oncology report: